Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Dilip Shanghvi to continue as the Executive Chairman of the Board
25 women students to receive internship, training, and mentorship in Life Sciences segment
Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Subscribe To Our Newsletter & Stay Updated